First high-content screening and analysis solution being used by bio-pharmaceutical researchers to identify off-target effects in live cells
IBM and Cellomics have launched a customised information technology (IT) solution that allows biopharmaceutical scientists and academic researchers to better understand how potential drug candidates or targets of interest affect cellular function.
The new solution, which allows for high-content screening and in-silico modeling is already being installed at Epoplus, a biopharmaceutical company developing a novel low-dose-erythropoietin therapy likely to have a major affect on the understanding of degenerative diseases, stem cell behavior and cell biology.
"We are very pleased to form this collaboration with IBM and Cellomics," said Ferdinand Bahlmann, president of Epoplus.
"The expertise and technology they provide greatly reduce the significant cost associated with screening and evaluating potential cell therapeutics".
By partnering with Cellomics, IBM is furthering its work in the field of information-based medicine, the process of improving existing pharmaceutical and medical practices with knowledge about the human genome.
The rich contextual data that can be obtained about cellular functions using HCS generates information necessary for modeling and simulation that empowers biopharmaceutical organizations to design more accurate trials, reducing time and cost spent making new drugs.
"In working with Cellomics to build this joint, turnkey solution, we're able to help organisations like Epoplus enhance their cellular research capabilities," said Mike Svinte, vice president, information-based medicine, IBM. "By putting this technology together in an out-of-the-box solution, we are hoping to give many more researchers the ability to test potential drug compounds against crucial, contextual information about cell structure, function and interaction". With the goal of delivering an IT solution that can automate and manage large volumes of data, IBM and Cellomics have combined Cellomics patented high content informatics (HCi) software with proven servers, storage and management software from IBM.
The resulting HCi appliance offers a scalable architecture that includes the Tivoli suite of security compliance products, IBM eServer, user training sessions and Cellomics Store, an enterprise-level database that stores and manages images and image-related data.
